Novartis Ilaris gains FDA OK in rare childhood arthritis
This article was originally published in Scrip
Executive Summary
Novartis won the US FDA's nod on 10 May to expand the indication of the company's interleukin-1 beta inhibitor (IL-1 beta) Ilaris (canakinumab) as a treatment for active systemic juvenile idiopathic arthritis (SJIA), a serious form of childhood arthritis, which can affect children as young as 2 years, continuing into adulthood.